Literature DB >> 11880418

Detection of neutralizing antibodies against human papillomaviruses (HPV) by inhibition of gene transfer mediated by HPV pseudovirions.

Latifa Bousarghin1, Alba-Lucia Combita-Rojas, Antoine Touzé, Slimane El Mehdaoui, Pierre-Yves Sizaret, Maria-Mercedes Bravo, Pierre Coursaget.   

Abstract

The goal of this study was to develop a human papillomavirus (HPV) neutralization assay using HPV pseudovirions generated in vitro. For this purpose, gene transfer efficiency of HPV virus-like particles (VLPs) was improved by using direct interaction between a reporter plasmid and the VLPs. Electron microscopic observation of the interaction between DNA molecules and VLPs revealed that VLPs always interact with a single DNA molecule and that VLPs bind to the end of linearized DNA molecules. An 100-fold improvement in the gene transfer was obtained by simple interaction between a linearized DNA molecule and VLPs. Moreover, direct interaction methods offer the possibility of transferring plasmids a size higher than that of the papillomavirus genome. The approach that we developed to generate HPV-16 and HPV-31 pseudovirions proved to be suitable for testing neutralizing antibodies in human sera both after immunization and after natural infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11880418      PMCID: PMC120236          DOI: 10.1128/JCM.40.3.926-932.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  43 in total

1.  Polymorphism in the assembly of polyomavirus capsid protein VP1.

Authors:  D M Salunke; D L Caspar; R L Garcea
Journal:  Biophys J       Date:  1989-11       Impact factor: 4.033

2.  Synthesis and assembly of infectious bovine papillomavirus particles in vitro.

Authors:  J Zhou; D J Stenzel; X Y Sun; I H Frazer
Journal:  J Gen Virol       Date:  1993-04       Impact factor: 3.891

3.  Identification of proteins encoded by the L1 and L2 open reading frames of human papillomavirus 1a.

Authors:  J Doorbar; P H Gallimore
Journal:  J Virol       Date:  1987-09       Impact factor: 5.103

4.  Cell-free assembly of a polyoma-like particle from empty capsids and DNA.

Authors:  S M Barr; K Keck; H V Aposhian
Journal:  Virology       Date:  1979-07-30       Impact factor: 3.616

5.  Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.

Authors:  R Kirnbauer; F Booy; N Cheng; D R Lowy; J T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

6.  Propagation of human papillomavirus type 11 in human xenografts using the severe combined immunodeficiency (SCID) mouse and comparison to the nude mouse model.

Authors:  W Bonnez; R C Rose; C Da Rin; C Borkhuis; K L de Mesy Jensen; R C Reichman
Journal:  Virology       Date:  1993-11       Impact factor: 3.616

7.  Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins.

Authors:  M E Hagensee; N Yaegashi; D A Galloway
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

8.  Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles.

Authors:  R C Rose; W Bonnez; R C Reichman; R L Garcea
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

9.  Detection of human serum antibodies that neutralize infectious human papillomavirus type 11 virions.

Authors:  N D Christensen; J W Kreider; K V Shah; R F Rando
Journal:  J Gen Virol       Date:  1992-05       Impact factor: 3.891

10.  The L2 open reading frame of human papillomavirus type 1a encodes a minor structural protein carrying type-specific antigens.

Authors:  C A Komly; F Breitburd; O Croissant; R E Streeck
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

View more
  7 in total

1.  Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice.

Authors:  Peter Ohlschläger; Wolfram Osen; Kerstin Dell; Stefan Faath; Robert L Garcea; Ingrid Jochmus; Martin Müller; Michael Pawlita; Klaus Schäfer; Peter Sehr; Caroline Staib; Gerd Sutter; Lutz Gissmann
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

2.  A comparative study of two different assay kits for the detection of secreted alkaline phosphatase in HPV antibody neutralization assays.

Authors:  Troy J Kemp; Ken Matsui; Gloriana Shelton; Mahboobeh Safaeian; Ligia A Pinto
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Human papillomavirus types 16, 31, and 58 use different endocytosis pathways to enter cells.

Authors:  Latifa Bousarghin; Antoine Touzé; Pierre-Yves Sizaret; Pierre Coursaget
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

4.  Detection of human papillomavirus type 31-neutralizing antibodies from naturally infected patients by an assay based on intracellular assembly of luciferase-expressing pseudovirions.

Authors:  Maxime J J Fleury; Antoine Touzé; Silvia de Sanjosé; F Xavier Bosch; Joellen Klaustermeiyer; Pierre Coursaget
Journal:  Clin Vaccine Immunol       Date:  2007-11-07

5.  Efficient delivery of DNA vaccines using human papillomavirus pseudovirions.

Authors:  S Peng; A Monie; T H Kang; C-F Hung; R Roden; T-C Wu
Journal:  Gene Ther       Date:  2010-07-29       Impact factor: 5.250

6.  Role of human papillomavirus types 16, 18, and 52 in recurrent cystitis and urinary bladder cancer among Egyptian patients.

Authors:  Hala Badawi; Hanem Ahmed; Ahmed Ismail; Manal Diab; Magd Moubarak; Afkar Badawy; Mohamed Saber
Journal:  Medscape J Med       Date:  2008-10-08

7.  Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31.

Authors:  M J J Fleury; A Touzé; E Alvarez; G Carpentier; C Clavel; J-F Vautherot; P Coursaget
Journal:  Arch Virol       Date:  2006-03-03       Impact factor: 2.574

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.